Literature DB >> 9336158

Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro.

W Budach1, D Gioioso, A Taghian, M Stuschke, H D Suit.   

Abstract

PURPOSE: Determination of clonogenic cell proliferation of three highly malignant squamous cell carcinomas (SCC) and two glioblastoma cell lines during a 20-day course of fractionated irradiation under in vitro conditions. METHODS AND MATERIALS: Tumor cells in exponential growth phase were plated in 24-well plastic flasks and irradiated 24 h after plating with 250 kV x-rays at room temperature. Six fractions with single doses between 0.6 and 9 Gy were administered in 1.67, 5, 10, 15, and 20 days. Colony growth was monitored for at least 60 days after completion of irradiation. Wells with confluent colonies were considered as "recurrences" and wells without colonies as "controlled." The dose required to control 50% of irradiated wells (WCD50) was estimated by a logistic regression for the different overall treatment times. The effective doubling time of clonogenic cells (T[eff]) was determined by a direct fit using the maximum likelihood method.
RESULTS: The increase of WCD50 within 18.3 days was highly significant for all tumor cell lines accounting for 7.9 and 12.0 Gy in the two glioblastoma cell lines and for 12.7, 14.0, and 21.7 Gy in the three SCC cell lines. The corresponding T(eff)s were 4.4 and 2.0 days for glioblastoma cell lines and 2.4, 4.2, and 1.8 days for SCC cell lines. Population doubling times (PDT) of untreated tumor cells ranged from 1.0 to 1.9 days, showing no correlation with T(eff)s. T(eff) was significantly longer than PDT in three of five tumor cell lines. No significant differences were observed comparing glioblastomas and SCC. Increase of WCD50 with time did not correlate with T(eff) but with T(eff) InSF2 (surviving fraction at 2 Gy).
CONCLUSION: The intrinsic ability of SCC and glioblastoma cells to repopulate during fractionated irradiation could be demonstrated. Repopulation induced dose loss per day depends on T(eff) and intrinsic radiation sensitivity. Proliferation during treatment was decelerated compared to pretreatment PDT in the majority of cell lines. Pretreatment cell kinetics did not predict for tumor cell proliferation during treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9336158     DOI: 10.1016/s0360-3016(97)00362-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Authors:  Haihui Jiang; Wei Zeng; Xiaohui Ren; Yong Cui; Mingxiao Li; Kaiyuan Yang; Mohammad Elbaroody; Song Lin
Journal:  J Neurooncol       Date:  2019-06-07       Impact factor: 4.130

Review 2.  New Hypofractionation Radiation Strategies for Glioblastoma.

Authors:  Melissa Azoulay; Jennifer Shah; Erqi Pollom; Scott G Soltys
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

3.  Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre.

Authors:  L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

4.  Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Authors:  Silvia Scoccianti; Marco Krengli; Livia Marrazzo; Stefano Maria Magrini; Beatrice Detti; Vincenzo Fusco; Luigi Pirtoli; Daniela Doino; Alba Fiorentino; Laura Masini; Daniela Greto; Michela Buglione; Giovanni Rubino; Federico Lonardi; Fernanda Migliaccio; Salvino Marzano; Riccardo Santoni; Umberto Ricardi; Lorenzo Livi
Journal:  Radiol Med       Date:  2017-09-06       Impact factor: 3.469

5.  Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).

Authors:  Mariangela Massaccesi; Marica Ferro; Savino Cilla; Mario Balducci; Francesco Deodato; Gabriella Macchia; Vincenzo Valentini; Alessio G Morganti
Journal:  Int J Clin Oncol       Date:  2012-08-15       Impact factor: 3.402

6.  Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation.

Authors:  D D Dionysiou; G S Stamatakos; D Gintides; N Uzunoglu; K Kyriaki
Journal:  Open Biomed Eng J       Date:  2008-09-10

Review 7.  Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

Authors:  M Hingorani; W P Colley; S Dixit; A M Beavis
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

8.  Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients.

Authors:  Eric Burton; Mehran Yusuf; Mark R Gilbert; Jeremy Gaskins; Shiao Woo
Journal:  J Geriatr Oncol       Date:  2019-09-11       Impact factor: 3.599

9.  Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy.

Authors:  Mehran B Yusuf; Jeremy Gaskins; Mark J Amsbaugh; Shiao Woo; Eric Burton
Journal:  Neurooncol Pract       Date:  2018-07-20

10.  Radiation sterilisation of cultured human brain tumour cells for clinical immune tumour therapy.

Authors:  C Bauréus-Koch; G Nyberg; B Widegren; L G Salford; B R R Persson
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.